Thera-SAbDab

RELATLIMAB

>   Structural Summary
TherapeuticRelatlimab
TargetLAG3
Heavy ChainQVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II/III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedBristol-Myers Squibb, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions Approvedna
Conditions ActiveMalignant melanoma, Colorectal cancer, Gastric cancer, Renal cell carcinoma, Solid tumours, Oesophageal cancer, Glioblastoma
Conditions DiscontinuedChronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Hodgkin's disease, Mantle-cell lymphoma, Non-Hodgkin's lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]